Titre : Hyperventilation

Hyperventilation : Questions médicales fréquentes

Termes MeSH sélectionnés :

Angiotensin Receptor Antagonists
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Hyperventilation : Questions médicales les plus fréquentes", "headline": "Hyperventilation : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Hyperventilation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-06", "dateModified": "2025-03-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Hyperventilation" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Signes et symptômes respiratoires", "url": "https://questionsmedicales.fr/mesh/D012818", "about": { "@type": "MedicalCondition", "name": "Signes et symptômes respiratoires", "code": { "@type": "MedicalCode", "code": "D012818", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.888.852" } } }, "about": { "@type": "MedicalCondition", "name": "Hyperventilation", "alternateName": "Hyperventilation", "code": { "@type": "MedicalCode", "code": "D006985", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Naoto Fujii", "url": "https://questionsmedicales.fr/author/Naoto%20Fujii", "affiliation": { "@type": "Organization", "name": "Faculty of Health and Sport Sciences, University of Tsukuba , Tsukuba , Japan." } }, { "@type": "Person", "name": "Takeshi Nishiyasu", "url": "https://questionsmedicales.fr/author/Takeshi%20Nishiyasu", "affiliation": { "@type": "Organization", "name": "Faculty of Health and Sport Sciences, University of Tsukuba , Tsukuba , Japan." } }, { "@type": "Person", "name": "Eun Hye Oh", "url": "https://questionsmedicales.fr/author/Eun%20Hye%20Oh", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Pusan National University School of Medicine, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea." } }, { "@type": "Person", "name": "Seo Young Choi", "url": "https://questionsmedicales.fr/author/Seo%20Young%20Choi", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea." } }, { "@type": "Person", "name": "Thomas Ritz", "url": "https://questionsmedicales.fr/author/Thomas%20Ritz", "affiliation": { "@type": "Organization", "name": "" } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Impact of the angiotensin receptor-neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls.", "datePublished": "2023-06-25", "url": "https://questionsmedicales.fr/article/37357546", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jdi.14044" } }, { "@type": "ScholarlyArticle", "name": "Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation.", "datePublished": "2023-02-23", "url": "https://questionsmedicales.fr/article/36823222", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-30349-w" } }, { "@type": "ScholarlyArticle", "name": "Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction.", "datePublished": "2023-06-22", "url": "https://questionsmedicales.fr/article/37345734", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jgs.18481" } }, { "@type": "ScholarlyArticle", "name": "Angiotensin receptor blockers in patients with hypertrophic cardiomyopathy: A comparison of VANISH and INHERIT randomized trials.", "datePublished": "2023-10-11", "url": "https://questionsmedicales.fr/article/37980092", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ahj.2023.08.013" } }, { "@type": "ScholarlyArticle", "name": "Angiotensin Receptor Blockers Restore Skeletal Muscle in Patients with Chronic Obstructive Pulmonary Disease.", "datePublished": "2023-09-21", "url": "https://questionsmedicales.fr/article/37741098", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.arcmed.2023.102890" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "États, signes et symptômes pathologiques", "item": "https://questionsmedicales.fr/mesh/D013568" }, { "@type": "ListItem", "position": 3, "name": "Signes et symptômes", "item": "https://questionsmedicales.fr/mesh/D012816" }, { "@type": "ListItem", "position": 4, "name": "Signes et symptômes respiratoires", "item": "https://questionsmedicales.fr/mesh/D012818" }, { "@type": "ListItem", "position": 5, "name": "Hyperventilation", "item": "https://questionsmedicales.fr/mesh/D006985" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Hyperventilation - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Hyperventilation", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-19", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Hyperventilation", "description": "Comment diagnostiquer l'hyperventilation ?\nQuels tests sont utilisés pour l'hyperventilation ?\nL'hyperventilation peut-elle être confondue avec d'autres conditions ?\nQuels signes cliniques indiquent l'hyperventilation ?\nL'hyperventilation est-elle mesurable ?", "url": "https://questionsmedicales.fr/mesh/D006985?mesh_terms=Angiotensin+Receptor+Antagonists&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Hyperventilation", "description": "Quels sont les symptômes courants de l'hyperventilation ?\nL'hyperventilation provoque-t-elle des douleurs thoraciques ?\nPeut-on ressentir de l'anxiété avec l'hyperventilation ?\nL'hyperventilation entraîne-t-elle une fatigue ?\nLes symptômes de l'hyperventilation sont-ils permanents ?", "url": "https://questionsmedicales.fr/mesh/D006985?mesh_terms=Angiotensin+Receptor+Antagonists&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Hyperventilation", "description": "Comment prévenir l'hyperventilation ?\nLes exercices de respiration aident-ils à prévenir l'hyperventilation ?\nL'éducation sur l'anxiété peut-elle prévenir l'hyperventilation ?\nLe yoga peut-il aider à prévenir l'hyperventilation ?\nLes techniques de méditation sont-elles utiles ?", "url": "https://questionsmedicales.fr/mesh/D006985?mesh_terms=Angiotensin+Receptor+Antagonists&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Hyperventilation", "description": "Quels traitements sont disponibles pour l'hyperventilation ?\nComment la thérapie comportementale aide-t-elle ?\nLes médicaments sont-ils nécessaires pour l'hyperventilation ?\nQuelles techniques de respiration sont recommandées ?\nL'hyperventilation nécessite-t-elle une hospitalisation ?", "url": "https://questionsmedicales.fr/mesh/D006985?mesh_terms=Angiotensin+Receptor+Antagonists&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Hyperventilation", "description": "Quelles complications peuvent survenir avec l'hyperventilation ?\nL'hyperventilation peut-elle causer des évanouissements ?\nDes troubles cardiaques peuvent-ils être liés à l'hyperventilation ?\nL'hyperventilation peut-elle affecter la santé mentale ?\nY a-t-il des risques à long terme liés à l'hyperventilation ?", "url": "https://questionsmedicales.fr/mesh/D006985?mesh_terms=Angiotensin+Receptor+Antagonists&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Hyperventilation", "description": "Quels sont les facteurs de risque de l'hyperventilation ?\nL'anxiété est-elle un facteur de risque ?\nLes athlètes sont-ils plus à risque d'hyperventilation ?\nLes maladies pulmonaires augmentent-elles le risque ?\nLe tabagisme est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D006985?mesh_terms=Angiotensin+Receptor+Antagonists&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer l'hyperventilation ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique et l'évaluation des symptômes respiratoires." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour l'hyperventilation ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de gaz du sang peuvent être effectués pour évaluer les niveaux de CO2." } }, { "@type": "Question", "name": "L'hyperventilation peut-elle être confondue avec d'autres conditions ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être confondue avec l'anxiété ou des troubles respiratoires." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent l'hyperventilation ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des palpitations, des étourdissements et des picotements peuvent indiquer l'hyperventilation." } }, { "@type": "Question", "name": "L'hyperventilation est-elle mesurable ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être mesurée par la fréquence respiratoire et les niveaux de CO2 dans le sang." } }, { "@type": "Question", "name": "Quels sont les symptômes courants de l'hyperventilation ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des vertiges, des palpitations, et des sensations de picotement." } }, { "@type": "Question", "name": "L'hyperventilation provoque-t-elle des douleurs thoraciques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut provoquer des douleurs thoraciques dues à une tension musculaire." } }, { "@type": "Question", "name": "Peut-on ressentir de l'anxiété avec l'hyperventilation ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'hyperventilation peut être à la fois un symptôme et un déclencheur d'anxiété." } }, { "@type": "Question", "name": "L'hyperventilation entraîne-t-elle une fatigue ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la fatigue peut survenir en raison d'une respiration inefficace et d'une hyperoxie." } }, { "@type": "Question", "name": "Les symptômes de l'hyperventilation sont-ils permanents ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Non, les symptômes sont généralement temporaires et liés à des épisodes de stress ou d'anxiété." } }, { "@type": "Question", "name": "Comment prévenir l'hyperventilation ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par la gestion du stress, des techniques de relaxation et une respiration consciente." } }, { "@type": "Question", "name": "Les exercices de respiration aident-ils à prévenir l'hyperventilation ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des exercices réguliers de respiration peuvent aider à stabiliser le rythme respiratoire." } }, { "@type": "Question", "name": "L'éducation sur l'anxiété peut-elle prévenir l'hyperventilation ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, comprendre l'anxiété et ses effets peut réduire les épisodes d'hyperventilation." } }, { "@type": "Question", "name": "Le yoga peut-il aider à prévenir l'hyperventilation ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le yoga favorise la relaxation et améliore la conscience respiratoire." } }, { "@type": "Question", "name": "Les techniques de méditation sont-elles utiles ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la méditation aide à réduire le stress et à réguler la respiration." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour l'hyperventilation ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des techniques de respiration, la thérapie cognitivo-comportementale et des médicaments." } }, { "@type": "Question", "name": "Comment la thérapie comportementale aide-t-elle ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Elle aide à gérer l'anxiété et à modifier les comportements de respiration inappropriés." } }, { "@type": "Question", "name": "Les médicaments sont-ils nécessaires pour l'hyperventilation ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Pas toujours, mais des anxiolytiques peuvent être prescrits si l'anxiété est sévère." } }, { "@type": "Question", "name": "Quelles techniques de respiration sont recommandées ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques comme la respiration diaphragmatique et la respiration lente sont recommandées." } }, { "@type": "Question", "name": "L'hyperventilation nécessite-t-elle une hospitalisation ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Rarement, sauf en cas de complications graves ou de crises d'anxiété sévères." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'hyperventilation ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles électrolytiques, des spasmes musculaires et des évanouissements." } }, { "@type": "Question", "name": "L'hyperventilation peut-elle causer des évanouissements ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une hyperventilation sévère peut entraîner des évanouissements en raison d'une hypoxie." } }, { "@type": "Question", "name": "Des troubles cardiaques peuvent-ils être liés à l'hyperventilation ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'hyperventilation peut provoquer des palpitations et des douleurs thoraciques, mais rarement des troubles cardiaques graves." } }, { "@type": "Question", "name": "L'hyperventilation peut-elle affecter la santé mentale ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut exacerber l'anxiété et mener à des troubles de l'humeur." } }, { "@type": "Question", "name": "Y a-t-il des risques à long terme liés à l'hyperventilation ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des risques à long terme incluent des problèmes respiratoires chroniques et des troubles anxieux." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de l'hyperventilation ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent le stress, l'anxiété, les troubles respiratoires et certaines conditions médicales." } }, { "@type": "Question", "name": "L'anxiété est-elle un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'anxiété est un facteur majeur qui peut déclencher des épisodes d'hyperventilation." } }, { "@type": "Question", "name": "Les athlètes sont-ils plus à risque d'hyperventilation ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les athlètes peuvent hyperventiler lors d'efforts intenses ou de stress compétitif." } }, { "@type": "Question", "name": "Les maladies pulmonaires augmentent-elles le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme l'asthme ou la BPCO peuvent augmenter le risque d'hyperventilation." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut aggraver les problèmes respiratoires et augmenter le risque d'hyperventilation." } } ] } ] }

Sources (10000 au total)

Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation.

Progression from paroxysmal to persistent atrial fibrillation (AF) is linked to adverse clinical outcomes. The present study sought to clarify whether angiotensin receptor-neprilysin inhibitor (ARNI) ...

Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction.

Frail older adults may be less likely to receive guideline-directed medical therapy (GDMT)-renin-angiotensin blockers, beta-blockers, and mineralocorticoid receptor antagonists-for heart failure with ... Using 2015-2019 Medicare data, we estimated the proportion of beneficiaries with HFrEF receiving ARNI and GDMT each year by frailty status, defined by a claims-based frailty index. Logistic regression... Among 147,506-180,386 beneficiaries with HFrEF (mean age: 77 years; 27% women; 42.6-49.1% frail) in 2015-2019, the proportion of patients receiving ARNI increased in both non-frail (0.4%-16.4%) and fr... Our results suggest an evidence-practice gap in the use of ARNI and GDMT in Medicare beneficiaries with HFrEF, particularly those with frailty. Efforts to narrow this gap are needed to reduce the burd...

Angiotensin receptor blockers in patients with hypertrophic cardiomyopathy: A comparison of VANISH and INHERIT randomized trials.

To identify the cause of discrepancy between the INHERIT trial and VANISH trial in regards to disease modification of angiotensin receptor II blockers in hypertrophic cardiomyopathy (HCM).... We replicated the data analysis used in VANISH, converting individual change in each component of the composite endpoint into a z-score and applying this z-score to the INHERIT results.... No significant improvement was identified in the composite z-score between the 2 groups at 12-month follow-up (P = .4). With the exception of tissue Doppler systolic (s') velocity, we found no signifi... Despite applying the potentially more sensitive composite z-score endpoint as in the VANISH trial, no statistically significant benefits from the use of losartan compared to placebo could be detected ...

Angiotensin Receptor Blockers Restore Skeletal Muscle in Patients with Chronic Obstructive Pulmonary Disease.

Age-related muscle decline, called sarcopenia, and hypertension are commonly observed in patients with chronic obstructive pulmonary disease (COPD). Angiotensin receptor blockers (ARBs) are common ant... We aimed to investigate the potential contribution of neuromuscular junction (NMJ) stability as a driving mechanism of ARBs-induced muscle protection.... We categorized 236 patients with COPD into normotensive (n = 79) and hypertensive, based on treatment with ARB (n = 82), and other antihypertensive drugs (n = 75). Hypertensive patients with COPD were... Patients with COPD exhibited reduced HGS and SPPB scores, and higher levels of CAF22 than controls, regardless of hypertension status. ARBs treatment improved HGS and gait speed and reduced plasma CAF... Altogether, ARB treatment preserves skeletal muscle health and functional capacity in hypertensive patients with COPD by reducing plasma CAF22 and possibly repairing NMJs....

Angiotensin receptor blockers might be protective against hepatic steatosis after liver transplantation.

Hepatic steatosis is an increasing complication in liver transplant recipients. Currently, there is no pharmacologic therapy for treatment of hepatic steatosis after liver transplantation. The aim of ... We conducted a case-control analysis on data from Shiraz Liver Transplant Registry. Liver transplant recipients with and without hepatic steatosis were compared for risk factors including use of ARB.... A total of 103 liver transplant recipients were included in the study. Thirty five patients treated with ARB and 68 patients (66%) did not receive these medications. In univariate analysis, ARB use (P... Our study showed that ARB use was associated with reduced incidence of hepatic steatosis in liver transplant recipients....

Nanotechnology-Based Strategies for Extended-Release Delivery of Angiotensin Receptor Blockers (ARBs): A Comprehensive Review.

There has been a significant shift in the perception of hypertension as an important contributor to the global disease burden. Approximately 6 % and 8 % of pregnancies are affected by hypertension, wh...

Incidence and Pattern of Aminotransferase Elevation During Anti-Hypertensive Therapy With Angiotensin-II Receptor Blockers.

Angiotensin type II receptor blockers (ARBs) are the most widely used anti-hypertensive drugs. This study aimed to elucidate the likelihood and pattern of ARB-induced liver injury in a hospital-based ... Data of patients receiving fimasartan (n = 5,543), candesartan (n = 6,406), valsartan (n = 6,040), and losartan (n = 9,126) were retrieved from the clinical data warehouse of two tertiary hospitals. P... A total of 27,115 patients were enrolled, including 14,630 (54.0%) men, with a mean age of 64.6 years (standard deviation, 13.6). During 31,717 person-years of ARB therapy, serum ALT levels > 120 IU/L... Approximately 2% of patients receiving ARB therapy had significant ALT elevation (4.24/10...

The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines.

Arterial hypertension is the main preventable cause of premature mortality worldwide. Across Latin America, hypertension has an estimated prevalence of 25.5-52.5%, although many hypertensive patients ...

Prophylactic effect of angiotensin receptor blockers in children with genetic aortopathies: the early bird catches the worm.

In genetic aortopathies (GA) particular attention is paid to aortic root dilatation which has an impact on morbidity and mortality. This study focuses on the effects of therapy with angiotensin-II-rec... Since 1998 we diagnosed 208 patients with GA (170 FBN-1). 81 patients between 5 months and 18 years receiving either ARB or BB therapy were included. We retrospectively analyzed the progression of the... Both ARB and BB (p < 0.05) therapy showed significant improvement in aortic root growth, while the effect is significantly more pronounced in ARB (p < 0.01) independent of age and genetic cause. A det... We demonstrated a significant change in both treatment options, with the effect of ARB being more pronounced while being better tolerated throughout the treatment period....